U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07634367) titled 'Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD' on June 03.
Brief Summary: This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD).
Study Start Date: July 10
Study Type: INTERVENTIONAL
Condition:
COPD (Chronic Obstructive Pulmonary Disease)
Intervention:
DRUG: HSK39004 Inhalation Suspension
Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg; Twice Daily for 52 weeks
Recruitment Status: NOT_YET_RECRUIT...